Metabolic Effects of Paricalcitol
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2009 |
| End Date: | October 2011 |
Effects of Oral Paricalcitol on Glucose Tolerance, Immune Cell Function, and Oxidative Stress in Stage 3-4 Chronic Kidney Disease
The purpose of this study is to determine if treatment with paricalcitol, an active form of
vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4
Chronic Kidney Disease (CKD).
Persons with chronic kidney disease (CKD) are at markedly increased risk of death,
particularly from cardiovascular disease (CVD). A number of metabolic abnormalities may
contribute to adverse health outcomes in CKD, including glucose intolerance, altered immune
cell function, and oxidative stress. Each of these metabolic stressors is a known
complication of CKD. Since these metabolic abnormalities are also known to contribute to the
pathogenesis of cardiovascular disease, they are important potential therapeutic targets in
CKD.
This study will test whether oral paricalcitol, an active form of vitamin D, will improve
glucose tolerance, immune cell function, and reduce oxidative stress in people with stage
3-4 chronic kidney disease.
We found this trial at
1
site
University of Washington Founded in 1861 by a private gift of 10 acres in what...
Click here to add this to my saved trials
